What were the treatment arms, and their duration, for the UNITI-1 and UNITI-2 induction studies?
A. Ustekinumab ~6 mg/kg or 130 mg, versus adalimumab over a 12-week period
B. Ustekinumab ~3 mg/kg or 220 mg versus vedolizumab over an 8-week period
C. Ustekinumab ~6 mg/kg or 130 mg, versus placebo over an 8-week period
D. Ustekinumab ~4 mg/kg versus adalimumab and placebo over a 12-week period
Preview next quiz:
What was the primary endpoint for the IM-UNITI study?
A. Clinical remission at Week 44
B. CDAI-70 response at Week 32
C. Clinical response at Week 44
D. CDAI score change of >100
Disclaimer:
Medical Quiz should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional. All content on this website is for informational and educational purposes only.